Literature DB >> 22878751

[Radiologic and nuclear medicine diagnosis and therapy of thyroid disorders: Part II: Malignant thyroid diseases].

C M Zechmann1, S Haufe.   

Abstract

Malignant thyroid diseases have increased in recent years. The distinction between differentiated and non-differentiated thyroid carcinoma is essential for therapy and follow-up. The frequently diagnosed papillary and follicular thyroid carcinomas are differentiated and have a good prognosis. Clinical symptoms are relatively unspecific, however imaging and laboratory testing can often provide evidence for diagnosis of thyroid carcinoma. Therapy typically involves surgery, ablative radioiodine therapy and subsequent suppressive hormone substitution. The pillars of follow-up are diagnostic scintigraphy, sonography and laboratory tests. Redifferentiation or a change of the tracer can make dedifferentiated tumors again susceptible to nuclide therapy. New treatment options have become available with the introduction of tyrosine kinase inhibitors.

Entities:  

Mesh:

Year:  2012        PMID: 22878751     DOI: 10.1007/s00117-012-2377-1

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  15 in total

1.  Cystic appearance of cervical lymph nodes is characteristic of metastatic papillary thyroid carcinoma.

Authors:  Ada Kessler; Yoram Rappaport; Annat Blank; Sylvia Marmor; Judith Weiss; Moshe Graif
Journal:  J Clin Ultrasound       Date:  2003-01       Impact factor: 0.910

2.  Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery.

Authors:  K Thomas Robbins; Garry Clayman; Paul A Levine; Jesus Medina; Roy Sessions; Ashok Shaha; Peter Som; Gregory T Wolf
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2002-07

Review 3.  The evolving role of (131)I for the treatment of differentiated thyroid carcinoma.

Authors:  Richard J Robbins; Martin J Schlumberger
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

4.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.

Authors:  Furio Pacini; Martin Schlumberger; Henning Dralle; Rossella Elisei; Johannes W A Smit; Wilmar Wiersinga
Journal:  Eur J Endocrinol       Date:  2006-06       Impact factor: 6.664

Review 5.  Papillary and follicular thyroid carcinoma.

Authors:  M J Schlumberger
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

6.  Does an undetectable rhTSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission?

Authors:  Joanna Klubo-Gwiezdzinska; Kenneth D Burman; Douglas Van Nostrand; Leonard Wartofsky
Journal:  Clin Endocrinol (Oxf)       Date:  2011-01       Impact factor: 3.478

7.  Survival of differentiated thyroid carcinoma studied in 500 patients.

Authors:  H Lerch; O Schober; T Kuwert; H B Saur
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

8.  Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.

Authors:  F Pacini; E Molinaro; M G Castagna; L Agate; R Elisei; C Ceccarelli; F Lippi; D Taddei; L Grasso; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

9.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns].

Authors:  S A Hundahl; I D Fleming; A M Fremgen; H R Menck
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

10.  Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma.

Authors:  Andrea Frasoldati; Marialaura Pesenti; Marco Gallo; Angelo Caroggio; Diana Salvo; Roberto Valcavi
Journal:  Cancer       Date:  2003-01-01       Impact factor: 6.860

View more
  3 in total

Review 1.  [Endocrine tumors: clinical overview].

Authors:  G Leidig-Bruckner
Journal:  Radiologe       Date:  2014-10       Impact factor: 0.635

Review 2.  [Radionuclide therapy of endocrine-related cancer].

Authors:  C Kratochwil; F L Giesel
Journal:  Radiologe       Date:  2014-10       Impact factor: 0.635

3.  [Endocrine tumors and their therapy].

Authors:  S Delorme; G Leidig-Bruckner; T Wilhelm
Journal:  Radiologe       Date:  2014-10       Impact factor: 0.635

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.